Published by Coherent Market Insights
Posted on September 27, 2021
“The Graft Versus Host Disease (GvHD) Market 2021 – 2027 report covers the important factors driving the growth of the market, untapped opportunities for manufacturers, trends and developments shaping the dynamics of the market and other insights across various key segments.”
Click Here To Get Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/184
Graft-versus-host disease (GvHD) is a systemic disorder and a common complication after allogeneic hematopoietic stem cell transplant. The condition can be subclassified into acute classic GVHD, persistent, recurrent, or late-onset acute GVHD, classic chronic GVHD, and overlap syndrome.
Market Dynamics
High adoption of hematopoietic stem cell transplantation and increasing prevalence of certain cancers of the blood or bone marrow, such as multiple myeloma or leukemia is expected to propel growth of the graft versus host disease (GvHD) market. For instance, according to Leukemia and Lymphoma Society, 176,200 people in the US are expected to be diagnosed with leukemia, lymphoma or myeloma in 2019. Moreover, around 30,000 patients undergo allogeneic hematopoietic stem cell transplant annually in the United States, with approximately 20% to 85% developing aGvHD that affects the skin, gut, or liver.
Increasing number of clinical trials for graft versus host disease is expected to offer lucrative growth opportunities for players in the graft versus host disease (GvHD) market. For instance, in January 2021, a two-stage, phase 2 clinical trial by Sherif S. Farag, Indiana University School of Medicine, reported that patients undergoing matched allogeneic stem-cell transplantation had a low incidence of graft-versus-host disease with the addition of the diabetes drug sitagliptin (Januvia) to standard prophylaxis. Moreover, launch of novel therapeutic platforms is also expected to aid in growth of the market. For instance, in September 2020, Avalon GloboCare Corp., a clinical-stage developer of cell-based technologies and therapeutics, launched its new allogeneic mesenchymal stromal cell therapeutic platform a potential therapy for COVID-19 and for bone marrow transplant related complications of acute graft versus host disease.
Major players operating in the graft versus host disease (GvHD) market are focused on R&D to expand their product portfolio. For instance, in December 2020, Mesoblast Limited presented biomarker evidence linking remestemcel-L’s immunomodulatory activity to survival outcomes in children with steroid-refractory acute graft versus host disease, at the 62nd annual meeting American Society of Hematology. Similarly, in November 2020, Equillium, Inc. announced positive interim data from the third cohort of the Phase 1b open label, dose escalation study of itolizumab in the first-line treatment of acute graft-versus-host disease.
Top Key Players Include In Graft Versus Host Disease (GvHD) Market: Sanofi, Novartis AG, Neovii Biotech GmbH, Merck & Co., Astellas Pharma Inc., Soligenix, Inc., and Mesoblast Ltd.
The Graft Versus Host Disease (GvHD) Market is displayed in 13 Chapters:
Chapter 1: Market Overview, Drivers, Restraints and Opportunities
Chapter 2: Market Competition by Manufacturers
Chapter 3: Production by Regions
Chapter 4: Consumption by Regions
Chapter 5: Production, By Types, Revenue and Market share by Types
Chapter 6: Consumption, By Applications, Market share (%) and Growth Rate by Applications
Chapter 7: Complete profiling and analysis of Manufacturers
Chapter 8: Manufacturing cost analysis, Raw materials analysis, Region-wise manufacturing expenses
Chapter 9: Industrial Chain, Sourcing Strategy and Downstream Buyers
Chapter 10: Marketing Strategy Analysis, Distributors/Traders
Chapter 11: Market Effect Factors Analysis
Chapter 12: Market Forecast
Chapter 13: Graft Versus Host Disease (GvHD) Research Findings and Conclusion, Appendix, methodology and data source
Get This premium report with Instant US$ 2000 discount @ https://www.coherentmarketinsights.com/promo/buynow/184
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Phone: US +12067016702 / UK +4402081334027
Email: sales@coherentmarketinsights.com
Visit Our Blog For More Such Reports: https://www.coherentmarketinsights.com/blog
The post Graft Versus Host Disease (GvHD) Market includes Production and Market Share by Type (2021-2027) appeared first on Gatorledger.
“The Graft Versus Host Disease (GvHD) Market 2021 – 2027 report covers the important factors driving the growth of the market, untapped opportunities for manufacturers, trends and developments shaping the dynamics of the market and other insights across various key segments.”
Click Here To Get Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/184
Graft-versus-host disease (GvHD) is a systemic disorder and a common complication after allogeneic hematopoietic stem cell transplant. The condition can be subclassified into acute classic GVHD, persistent, recurrent, or late-onset acute GVHD, classic chronic GVHD, and overlap syndrome.
Market Dynamics
High adoption of hematopoietic stem cell transplantation and increasing prevalence of certain cancers of the blood or bone marrow, such as multiple myeloma or leukemia is expected to propel growth of the graft versus host disease (GvHD) market. For instance, according to Leukemia and Lymphoma Society, 176,200 people in the US are expected to be diagnosed with leukemia, lymphoma or myeloma in 2019. Moreover, around 30,000 patients undergo allogeneic hematopoietic stem cell transplant annually in the United States, with approximately 20% to 85% developing aGvHD that affects the skin, gut, or liver.
Increasing number of clinical trials for graft versus host disease is expected to offer lucrative growth opportunities for players in the graft versus host disease (GvHD) market. For instance, in January 2021, a two-stage, phase 2 clinical trial by Sherif S. Farag, Indiana University School of Medicine, reported that patients undergoing matched allogeneic stem-cell transplantation had a low incidence of graft-versus-host disease with the addition of the diabetes drug sitagliptin (Januvia) to standard prophylaxis. Moreover, launch of novel therapeutic platforms is also expected to aid in growth of the market. For instance, in September 2020, Avalon GloboCare Corp., a clinical-stage developer of cell-based technologies and therapeutics, launched its new allogeneic mesenchymal stromal cell therapeutic platform a potential therapy for COVID-19 and for bone marrow transplant related complications of acute graft versus host disease.
Major players operating in the graft versus host disease (GvHD) market are focused on R&D to expand their product portfolio. For instance, in December 2020, Mesoblast Limited presented biomarker evidence linking remestemcel-L’s immunomodulatory activity to survival outcomes in children with steroid-refractory acute graft versus host disease, at the 62nd annual meeting American Society of Hematology. Similarly, in November 2020, Equillium, Inc. announced positive interim data from the third cohort of the Phase 1b open label, dose escalation study of itolizumab in the first-line treatment of acute graft-versus-host disease.
Top Key Players Include In Graft Versus Host Disease (GvHD) Market: Sanofi, Novartis AG, Neovii Biotech GmbH, Merck & Co., Astellas Pharma Inc., Soligenix, Inc., and Mesoblast Ltd.
The Graft Versus Host Disease (GvHD) Market is displayed in 13 Chapters:
Chapter 1: Market Overview, Drivers, Restraints and Opportunities
Chapter 2: Market Competition by Manufacturers
Chapter 3: Production by Regions
Chapter 4: Consumption by Regions
Chapter 5: Production, By Types, Revenue and Market share by Types
Chapter 6: Consumption, By Applications, Market share (%) and Growth Rate by Applications
Chapter 7: Complete profiling and analysis of Manufacturers
Chapter 8: Manufacturing cost analysis, Raw materials analysis, Region-wise manufacturing expenses
Chapter 9: Industrial Chain, Sourcing Strategy and Downstream Buyers
Chapter 10: Marketing Strategy Analysis, Distributors/Traders
Chapter 11: Market Effect Factors Analysis
Chapter 12: Market Forecast
Chapter 13: Graft Versus Host Disease (GvHD) Research Findings and Conclusion, Appendix, methodology and data source
Get This premium report with Instant US$ 2000 discount @ https://www.coherentmarketinsights.com/promo/buynow/184
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Phone: US +12067016702 / UK +4402081334027
Email: sales@coherentmarketinsights.com
Visit Our Blog For More Such Reports: https://www.coherentmarketinsights.com/blog
The post Graft Versus Host Disease (GvHD) Market includes Production and Market Share by Type (2021-2027) appeared first on Gatorledger.
